The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 662, Issue 1-2, 2009, Pages 67-74

  Birtwistle, Jane ^a   Hayden, Rachel E ^a   Khanim, Farhat L ^a   Green, Richard M ^a   Pearce, Claire ^a   Davies, Nicholas J ^a   Wake, Naomi ^a   Schrewe, Heiner ^b,c   Ride, Jonathan P ^a   Chipman, James K ^a   Bunce, Chris M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AKR1C3; Carcinogen activation; Differentiation; K562; PAH; Prostaglandin D2 metabolism

Indexed keywords

7,12 DIMETHYLBENZ(A)ANTHRACENE 3,4 DIHYDRODIOL; AKR1C3 PROTEIN; DNA; OXIDOREDUCTASE; POLYCYCLIC AROMATIC HYDROCARBON; PROSTAGLANDIN D2; RNA; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; COMET ASSAY; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

3-HYDROXYSTEROID DEHYDROGENASES; 9,10-DIMETHYL-1,2-BENZANTHRACENE; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA DAMAGE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; GLYCOPHORIN; HEMOGLOBINS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; OXIDATIVE STRESS; STEM CELLS;

EID: 60449106323     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2008.12.010     Document Type: Article

References (27)

1. Finette B.A., O'Neill J.P., Vacek P.M., and Albertini R.J. Gene mutations with characteristic deletions in cord blood T lymphocytes associated with passive maternal exposure to tobacco smoke. Nat. Med. 4 (1998) 1144-1151
2. Ji B.T., Shu X.O., Linet M.S., Zheng W., Wacholder S., Gao Y.T., Ying D.M., and Jin F. Paternal cigarette smoking and the risk of childhood cancer among offspring of nonsmoking mothers. J. Natl. Cancer Inst. 89 (1997) 238-244
3. Korte J.E., Hertz-Picciotto I., Schulz M.R., Ball L.M., and Duell E.J. The contribution of benzene to smoking-induced leukemia. Environ. Health Perspect. 108 (2000) 333-339
4. Bjork J., Johansson B., Broberg K., and Albin M. Smoking as a risk factor for myelodysplastic syndromes and acute myeloid leukemia and its relation to cytogenetic findings: a case-control study. Leuk. Res. (2008)
5. Desmond J.C., Mountford J.C., Drayson M.T., Walker E.A., Hewison M., Ride J.P., Luong Q.T., Hayden R.E., Vanin E.F., and Bunce C.M. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res. 63 (2003) 505-512
6. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., Moore M., Palackal N., and Ratnam K. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351 (2000) 67-77
7. Suzuki-Yamamoto T., Nishizawa M., Fukui M., Okuda-Ashitaka E., Nakajima T., Ito S., and Watanabe K. cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett. 462 (1999) 335-340
8. Burczynski M.E., Harvey R.G., and Penning T.M. Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry 37 (1998) 6781-6790
9. Palackal N.T., Lee S.H., Harvey R.G., Blair I.A., and Penning T.M. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J. Biol. Chem. 277 (2002) 24799-24808
10. Smithgall T.E., Harvey R.G., and Penning T.M. Regio- and stereospecificity of homogeneous 3 alpha-hydroxysteroid-dihydrodiol dehydrogenase for trans-dihydrodiol metabolites of polycyclic aromatic hydrocarbons. J. Biol. Chem. 261 (1986) 6184-6191
11. Yang S.K., McCourt D.W., Roller P.P., and Gelboin H.V. Enzymatic conversion of benzo(a)pyrene leading predominantly to the diol-epoxide r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene through a single enantiomer of r-7,t-8-dihydroxy-7,8-dihydrobenzo(a)pyrene. Proc. Natl. Acad. Sci. USA 73 (1976) 2594-2598
12. Park J.H., Mangal D., Tacka K.A., Quinn A.M., Harvey R.G., Blair I.A., and Penning T.M. Evidence for the aldo-keto reductase pathway of polycyclic aromatic trans-dihydrodiol activation in human lung A549 cells. Proc. Natl. Acad. Sci. USA 105 (2008) 6846-6851
13. Tsuruda L., Hou Y., and Penning T.M. Stable expression of rat dihydrodiol dehydrogenase (AKR1C9) in human breast MCF-7 cells results in the formation of PAH-o-quinones and enzyme mediated cell death. Chem. Res. Toxicol. 14 (2001) 856-862
14. Kunath T., Gish G., Lickert H., Jones N., Pawson T., and Rossant J. Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nat. Biotechnol. 21 (2003) 559-561
15. Ji Q., Chang L., VanDenBerg D., Stanczyk F.Z., and Stolz A. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 54 (2003) 275-289
16. Honda A., Morita I., Murota S., and Mori Y. Appearance of the arachidonic acid metabolic pathway in human promyelocytic leukemia (HL-60) cells during monocytic differentiation: enhancement of thromboxane synthesis by 1 alpha,25-dihydroxyvitamin D-3. Biochim. Biophys. Acta 877 (1986) 423-432
17. Green R.M., Graham M., O'Donovan M.R., Chipman J.K., and Hodges N.J. Subcellular compartmentalization of glutathione: correlations with parameters of oxidative stress related to genotoxicity. Mutagenesis 21 (2006) 383-390
18. Byrns M.C., Steckelbroeck S., and Penning T.M. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. 75 (2008) 484-493
19. Agarwal A.K., and Auchus R.J. Minireview: cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency. Endocrinology 146 (2005) 2531-2538
20. Gilliland D.G., Jordan C.T., and Felix C.A. The molecular basis of leukemia. Hematol. Am. Soc. Hematol. Educ. Program (2004) 80-97
21. Liu C.Y., Hsu Y.H., Pan P.C., Wu M.T., Ho C.K., Su L., Xu X., Li Y., and Christiani D.C. Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia. Carcinogenesis (2008)
22. Kasum C.M., Blair C.K., Folsom A.R., and Ross J.A. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 534-537
23. Pogoda J.M., Preston-Martin S., Nichols P.W., and Ross R.K. Smoking and risk of acute myeloid leukemia: results from a Los Angeles County case-control study. Am. J. Epidemiol. 155 (2002) 546-553
24. Lozzio C.B., and Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45 (1975) 321-334
25. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
26. Lan Q., Mumford J.L., Shen M., Demarini D.M., Bonner M.R., He X., Yeager M., Welch R., Chanock S., Tian L., Chapman R.S., Zheng T., Keohavong P., Caporaso N., and Rothman N. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 25 (2004) 2177-2181
27. Greaves M. Darwinian medicine: a case for cancer. Nat. Rev. Cancer 7 (2007) 213-221